Kerala Ayurveda Ltd
BSE:530163
Kerala Ayurveda Ltd
BSE:530163
Price:
180.65
INR
4.51%
Market Closed
Market Cap:
₹2.2B
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
Kerala Ayurveda Ltd
BSE:530163
|
IN |
|
Residential Secure Income PLC
LSE:RESI
|
UK |
|
Scatec ASA
OSE:SCATC
|
NO |
|
G
|
G Mining Ventures Corp
XTSX:GMIN
|
CA |
|
Ros Agro PLC
LSE:AGRO
|
CY |
|
Chesapeake Utilities Corp
NYSE:CPK
|
US |
|
Foran Energy Group Co Ltd
SZSE:002911
|
CN |
|
AbraSilver Resource Corp
XTSX:ABRA
|
CA |
|
DLP Resources Inc
XTSX:DLP
|
CA |
|
H
|
Hextar Capital Bhd
KLSE:HEXCAP
|
MY |
|
NWF Group PLC
LSE:NWF
|
UK |
|
Internetworking and Broadband Consulting Co Ltd
TSE:3920
|
JP |
|
Hengdian Group DMEGC Magnetics Co Ltd
SZSE:002056
|
CN |
|
Beijing Huafeng Test & Control Technology Co Ltd
SSE:688200
|
CN |
|
R
|
Reem Capital Corp
XTSX:REEM.P
|
CA |
|
C&C Group PLC
LSE:CCR
|
IE |
|
B
|
Bhilwara Technical Textiles Ltd
BSE:533108
|
IN |
Multiples-Based Value
The Multiples-Based Value of one
KERALAYUR
stock under the Base Case scenario is
hidden
INR.
Compared to the current market price of 180.65 INR,
Kerala Ayurveda Ltd
is
hidden
.
Multiples-Based Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
KERALAYUR Multiples-Based Value
LOCKED
Multiples Across Competitors
KERALAYUR Competitors Multiples
Kerala Ayurveda Ltd Competitors
Kerala Ayurveda Ltd Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| IN |
|
Kerala Ayurveda Ltd
BSE:530163
|
2.2B INR | 1.7 | -9.2 | -10.8 | -8.7 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
829.8B USD | 12.7 | 40.2 | 27.2 | 29 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
579B USD | 6.1 | 21.6 | 15 | 18.4 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF | 4 | 19.3 | 11.5 | 12.9 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
296B USD | 4.6 | 16.2 | 10 | 12.2 | |
| CH |
|
Novartis AG
SIX:NOVN
|
229.3B CHF | 5.2 | 21.1 | 13 | 16.8 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
214.5B GBP | 5.1 | 29.1 | 16.1 | 22.7 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
237.1B USD | 102.3 | -81.1 | 375.3 | 941.3 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1T DKK | 3.3 | 9.8 | 7.3 | 8.6 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
153.7B USD | 2.5 | 19.8 | 7.6 | 10.2 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
117.8B USD | 2.4 | 16.7 | 7.1 | 8.7 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
